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Abstract
Background: Previous population-based studies on second primary cancers (SPCs) in
urothelial cancers have focused on known risk factors in bladder cancer patients
without data on other urothelial sites of the renal pelvis or ureter.
Aims: To estimate sex-specific risks for any SPCs after urothelial cancers, and in
reverse order, for urothelial cancers as SPCs after any cancer. Such two-way analysis
may help interpret the results.
Methods: We employed standardized incidence ratios (SIRs) to estimate bidirectional
relative risks of subsequent cancer associated with urothelial cancers. Patient data
were obtained from the Swedish Cancer Registry from years 1990 through 2015.
Results: We identified 46 234 urinary bladder cancers (75% male), 940 ureteral can-
cers (60% male), and 2410 renal pelvic cancers (57% male). After male bladder cancer,
SIRs significantly increased for 9 SPCs, most for ureteral (SIR 41.9) and renal pelvic
(17.2) cancers. In the reversed order (bladder cancer as SPC), 10 individual FPCs were
associated with an increased risk; highest associations were noted after renal pelvic
(21.0) and ureteral (20.9) cancers. After female bladder cancer, SIRs of four SPCs were
significantly increased, most for ureteral (87.8) and pelvic (35.7) cancers. Female blad-
der, ureteral, and pelvic cancers associated are with endometrial cancer.
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Conclusions: The risks of recurrent urothelial cancers were very high, and, at most sites,
female risks were twice over the male risks. Risks persisted often to follow-up periods of
>5 years, motivating an extended patient follow-up. Lynch syndrome-related cancers
were associatedwith particularly female urothelial cancers, calling for clinical vigilance.
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1 | INTRODUCTION
Urothelial carcinomas include bladder cancer (90-95% of all) and cancer
of the upper urinary tract (UUT), of which two-thirds are located in the
renal pelvis and the remaining in the ureter.1 Bladder cancer is charac-
terized by male excess, ranging from three- to sixfold.2,3 International
incidence trends have found correlation with the regional smoking
prevalence.2,4 Bladder cancer incidence in Swedish men has been low
and relatively stable at about 20/100 000, while for women, the rate
has increased, reaching an incidence of about 6/100 000.5,6 Smoking
prevalence is not the only explanation to the sex difference in bladder
cancer incidence in Sweden, because smoking prevalence in men and
women has been approximately equal since 1980 and dropping from
30% to below 10%; around 1950, half of men smoked compared to
10% of women6 (www.pnlee.co.uk/downloads/iss/iss-sweden_
111024.pdf). UUT cancers show also male excess.1 All urothelial can-
cers share a number of risk factors, including smoking, occupational
exposures, family history, and association with Lynch syndrome.1,7-9
However, while smoking appears to be the main risk factor for bladder
cancer compared to Lynch syndrome, the opposite may be the case for
UUT cancers.10,11 Colorectal cancer and endometrial cancers are tradi-
tional hallmarks of Lynch syndrome (www.lscarisk.org).12,13 Few guide-
lines to date suggest urological follow-up with Lynch patients.1
In Sweden, survival has slightly improved for bladder cancer since
about 1980.14-16 In 2012-2016, the relative 5-year survival for female
bladder cancer was 72% but it was higher, 77% for men (http://www-
dep.iarc.fr/NORDCAN/english/frame.asp). Early detection, novel
imaging technologies, and improvements in treatment have contrib-
uted to positive trends in bladder cancer survival.5 At bladder cancer
diagnosis, some 20-25% of patients present with muscle invasive
tumors, and the remaining patients have superficial tumors, which can
later progress to invasive cancer.17 Surgery is the main treatment
mode for urothelial cancers. For bladder cancer, non-muscle-invasive
tumors are transuretherally resected while muscle-invasive tumors are
typically treated with cystectomy; both of which can be supplemented
with chemotherapy or immunotherapy.5,17 Radiotherapy may be used
for bladder preservation.18 For UUT cancers, treatment may involve
removal of the ipsilateral ureter and kidney.1
Improved survival implies that the likelihood of second primary
cancers (SPCs) increases. SPCs after bladder cancer show typically
high risks of tobacco-related cancers of the lung and head and
neck.19-22 Studies on SPCs in UUT cancer patients are limited, and
one of the problems is to distinguish independent SPCs from
recurrences.21 Recurrence of UUT urothelial cancer into the bladder is
relatively common, while seeding from the bladder into UUT is
rarer.1,23-25 Plausible etiologies for SPCs are many, but probably the
most important ones are intensive medical surveillance after the diag-
nosis of first primary cancer (FPC), therapy for FPC, shared genetic or
nongenetic risk factors between FPC and SPC and immune dysfunc-
tion, or interactions between these.26-28 As data on the possible risk
factors for SPC are usually limited, we have devised a bidirectional
analysis as a tool to help etiological search.26-29
In this analysis, we want to define risks for specific subsequent
cancers related to bladder and UUT cancers using Swedish nation-
wide data. Risks for SPCs are assessed pair-wise as FPC and SPC, that
is, the standardized incidence ratio (SIR) of lung cancer was assessed
after bladder cancer, and, alternatively, SIR of bladder cancer was
assessed after lung cancer. The bidirectional analysis will help to dis-
tinguish, at least to some extent, the influence of treatment and medi-
cal surveillance on SIR because two different cancers are usually
treated and diagnosed in different ways. As the previous literature has
focused on SPCs after bladder cancer, we hypothesized that the novel
type of bidirectional analysis will be able to produce novel qualified
data on risks for bladder and UUT cancers.
2 | MATERIALS AND METHODS
2.1 | Diagnostic codes and nomenclature
We considered bladder and UUT cancers diagnosed from 1990 to 2015
in the Swedish Cancer Registry using International Classification of Dis-
eases (ICD) version 7 and later codes. The project database is located at
the Center for Primary Health Care Research in Malmö, Sweden.
Code 1810 was used for bladder cancers and, of these, 98% are
transitional cell carcinomas.30 The code for ureter cancer was 1811.31
Urethral cancer was not considered because of its rarity and late
introduction of a specific diagnostic code. Kidney cancer (ie, renal
+ pelvis/calyx) was identified with code 180, renal cell cancer (RCC)
with code 1800, and pelvic/calyx cancer with 1801. The correctness
of classification of UUT cancer in the Cancer Registry has been evalu-
ated, and 93% were found to be correct; the misclassification fre-
quently involved other urinary tract tumors.32 In this article, we
consider a possible “recurrence” when a second urothelial cancer
occurred at the same anatomic site or at another urothelial site,
following the practice of the European Association of Urology.1
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2.2 | Patient follow-up periods and methods
Bladder and UUT cancer patients were followed from year 1990 through
year 2015 for diagnosis of any common SPC, and, conversely in a reverse
order, any common cancer was FPC and bladder, and UUT cancers were
SPCs. The other cancers include any of 21 common male and 22 female
primary cancers. For a proper bidirectional analysis, we excluded cancers
for which 1-year survival was less than 50% (esophagus, pancreas).
Patients were followed for SPCs from the diagnosis of FPC until the end
of 2015 or immigration or death, whichever came earliest. Only discor-
dant (different) FPC-SPC pairs were included without applying any lag
time between the two diagnoses. The upper aerodigestive tract (UAT)
included the lip, oral cavity, pharynx, and larynx. For skin cancer, only
squamous cell carcinoma (SCC) was included. For the risk of “all” cancers,
bladder and UUT cancers were excluded. The SIR for “all” cancers was
weighed according to person-years at risk. No latency time was apply
between diagnoses of FPC and SPC because in the Swedish Cancer Reg-
istry, practically all cancers are histologically verified and thus true can-
cers.31 The application of a latency time would have caused bias because
a large number of true SPCs would have been missed.
2.3 | Calculation of relative risk
Sex-specific SIRs were calculated to measure the risk of SPCs as the
ratio of observed to expected number of cases. For risk of a certain
SPC, the expected number of cases was calculated by strata-specific
person years in patients with diagnosis of first primary bladder or
UUT cancers, multiplied by strata-specific incidence rates of the same
SPC as FPC in the general population. The strata were specified by sex,
5-year age group, 5-year-calendar period, socioeconomic status, and
place of residence. In the reverse analysis, SIRs for second bladder and
UUT cancers were calculated in the same way. The two-tailed 95%
confidence intervals (95% CIs) of SIRs were calculated by assuming a
Poisson distribution. The expected numbers can be obtained by divid-
ing observed numbers with SIR. The method of SIR calculation is based
on indirect standardization, and it is particularly suitable for datasets
with small case numbers because the expected numbers are calculated
from the large background population, all Sweden in this case.33
Bidirectional SIRs for bladder cancer were summarized in forest
plots. Pearson correlation coefficient was used to estimate the relation
between the bidirectional SIRs for bladder cancer (FPC vs SPC) as well as
the SIRs of the common cancers in men and women (men vs women). In
addition, we carried out period-specific analysis by calculating SIRs during
1, 2-5, and >5 years after first primary cancer diagnosis. All the statistical
analyses were performed in SAS 9.4, and forest plot was generated in R
3.3.6. In order to simplify the tables, we did not show data for cancers
with less than five cases in any comparison, unless the SIRwas significant.
The difference between two SIRs was considered significant when their
95%CIs did not overlap. Only significant SIRs were commented on. In the
tables, some lines for the urothelial cancers were repeated in the reverse
analyses, but theywere kept to help comparisons.
3 | RESULTS
During the follow-up (inclusion) period of 1990 to 2015, we identified
46 234 bladder cancers, 940 ureter cancers, and 2410 renal pelvic
cancers (Table 1). The total number of other cancers considered as
SPCs or FPCs was 513 693 for men and 496 600 for women in the
concurrent Swedish population of 6.2 million men and 6.2 million women.
Bidirectional SIRs for male SPCs for bladder and UUT cancers are
shown in Table 2. After bladder cancer, SIRs were significantly increased
for 10 SPCs (counting RCC and renal pelvis but not kidney), most for
ureteral (SIR 41.9), renal pelvic (17.20), and small intestinal (2.38) can-
cers. SIR for RCC was 2.20. The overall SIR for any SPC was 1.56. In the
reversed order (bladder cancer as SPC), 10 individual FPCs were associ-
ated with an increased risk; highest associations were noted after renal
pelvic (21.0), ureteral (20.9), and testicular (2.01) cancers. Second blad-
der cancer risk was 1.45 after RCC. The SIR for all cancers was 1.28.
Only five cancers (ureteral, pelvic, RCC, lung and prostate cancers) were
bidirectionally associated. For six cancer pairs, the bidirectional SIRs dif-
fered significantly (ie, the 95% CIs did not overlap); for ureteral, stom-
ach, lung, RCC, and prostate cancers, the SIRs were higher when these
cancers were SPCs than in the reverse order; for skin SCC, the opposite
was the case. The data are summarized in Figure 1A.
For ureteral cancer, second RCC (6.46), pelvic (108.6), and bladder
(20.9) cancers were the only significantly increased SPCs (Table 2).
Bladder cancer accounted for half of all SPCs. Ureteral cancer as SPC
was associated with renal pelvic (129.0, the highest risk recoded in
this study) and bladder (41.9) cancers. After renal pelvic cancer, blad-
der (21.0) and ureteral (129.0) cancers were increased. Bladder cancer
accounted for more than half of all SPCs. In the reverse order, the
same cancers and RCC (3.94) showed associations.
Similar analysis is shown for female cancer in Table 3. After
bladder cancer, SIRs of five SPCs were significantly increased, includ-
ing ureteral (87.8), pelvic (35.7), RCC (2.26), lung (2.82), and skin (1.23)
cancers. The overall risk was 1.46. In the reverse order (bladder cancer
TABLE 1 Number and median age at diagnosis of the bladder and upper urinary tract cancers identified from 1990 to 2015
Cancer
N (percentage) Median (lower and upper quartiles) age at diagnosis
Male Female Male Female
Bladder 34 676 (75%) 11 558 (25%) 73 (65-80) 74 (65-82)
Ureter 564 (60%) 376 (40%) 72 (65-79) 74 (67-80)
Renal pelvic 1374 (57%) 1036 (43%) 77 (63-77) 73 (65-80)
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TABLE 2 Male risks of SPCs after bladder, ureteral, and renal pelvic cancers and these cancers as SPCs
Cancer A Cancer B
Cancer A followed by cancer B Cancer B followed by cancer A
N SIR 95% CI N SIR 95% CI
Bladder UAT 110 1.18 0.97 1.43 143 1.51 1.28 1.78
Stomach 141 1.28 1.08 1.51 46 0.75 0.55 1.01
Small intestine 41 2.38 1.71 3.23 19 1.37 0.82 2.15
CRC 564 1.08 0.99 1.17 521 1.11 1.02 1.21
Liver 117 1.41 1.17 1.69 23 0.78 0.50 1.17
Lung 683 2.08 1.93 2.25 174 1.31 1.12 1.52
Breast 10 1.52 0.72 2.81 9 1.34 0.61 2.56
Prostate 2832 1.73 1.67 1.8 2518 1.25 1.20 1.30
Testis 5 1.41 0.45 3.32 23 2.01 1.27 3.01
Male genital 5 0.35 0.11 0.83 19 1.31 0.79 2.05
Kidney 369 3.98 3.58 4.4 309 3.54 3.16 3.96
RCC 140 2.20 1.85 2.60 97 1.45 1.17 1.77
Renal pelvis 195 17.2 14.9 19.8 199 21.0 18.2 24.1
Ureter 211 41.9 36.4 48.0 83 20.9 16.6 25.9
Melanoma 135 0.93 0.78 1.1 174 1.08 0.92 1.25
Skin SCC 364 0.95 0.86 1.05 337 1.35 1.21 1.51
Nervous system 61 1.17 0.89 1.5 49 0.96 0.71 1.26
Thyroid 15 1.54 0.86 2.54 13 1.18 0.62 2.02
Endocrine 41 1.68 1.21 2.28 48 1.14 0.84 1.51
Connective tissue 29 1.33 0.89 1.91 27 1.34 0.88 1.95
NHL 7 1.21 0.48 2.51 12 1.80 0.93 3.15
Hodgkin lymphoma 140 1.06 0.89 1.25 141 1.29 1.08 1.52
Myeloma 56 0.95 0.72 1.23 24 0.58 0.37 0.87
Leukemia 151 1.23 1.04 1.44 106 1.11 0.91 1.35
All 6510 1.56 1.53 1.60 4919 1.28 1.25 1.32
Ureter CRC 5 0.85 0.27 2.00 9 1.22 0.55 2.32
Lung 8 2.12 0.91 4.20 2 0.90 0.09 3.32
Prostate 20 1.07 0.65 1.66 32 1.00 0.69 1.42
Kidney 20 17.9 10.93 27.74 20 14.2 8.67 22.0
RCC 5 6.46 2.04 15.2 2 1.84 0.17 6.76
Renal pelvis 14 108.6 59.2 182.8 18 129.0 76.3 204.3
Bladder 83 20.9 16.6 25.9 211 41.9 36.4 48.0
All 167 2.99 2.56 3.48 293 4.46 3.96 5.00
Renal pelvis CRC 12 0.85 0.43 1.48 22 1.32 0.83 2.00
Lung 13 1.39 0.74 2.39 13 1.12 0.40 2.46
Prostate 54 1.17 0.88 1.53 86 1.19 0.95 1.46
RCC 5 2.64 0.83 6.22 10 3.94 2.70 12.5
Bladder 199 21.0 18.2 24.1 195 17.2 14.9 19.8
Ureter 18 129.0 76.3 204.3 14 108.6 59.2 182.8
All 357 2.73 2.40 3.03 380 2.53 2.28 2.80
Note: Bold values show that the 95% CI does not overlap with 1.00.
Abbreviations: CRC, colorectal cancer; N, patient number; NHL, non-Hodgkin lymphoma; RCC, renal cell carcinoma; SCC, squamous cell carcinoma; SIR,
standardized incidence ratio; SPC, second primary cancer; UAT, upper aerodigestive tract; 95% CI, 95% confidence interval.
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F IGURE 1 Forest plot on standardized
incidence ratios (SIRs) of second primary
cancers (SPCs) after urinary bladder cancer and
that of urinary bladder cancer after other
cancers in men (A) and women (B). SIR for all
cancers excluded bladder cancer. SPC, second
primary cancer; SIR, standardized incidence
ratio; UAT, upper aerodigestive tract; NHL, non-
Hodgkin lymphoma
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TABLE 3 Female risks of SPCs after bladder, ureteral, and renal pelvic cancers and these cancer as SPCs
Cancer A Cancer B
Cancer A followed by cancer B Cancer B followed by cancer A
N SIR 95% CI N SIR 95% CI
Bladder UAT 17 1.20 0.70 1.93 12 0.91 0.47 1.6
Stomach 21 1.15 0.71 1.76 15 1.43 0.80 2.37
Small intestine 8 1.86 0.80 3.69 4 1.10 0.29 2.85
CRC 148 1.14 0.97 1.34 183 1.51 1.30 1.75
Liver 27 1.23 0.81 1.8 3 0.37 0.07 1.09
Lung 181 2.82 2.43 3.26 49 1.81 1.34 2.4
Breast 240 1.11 0.97 1.26 382 1.18 1.07 1.31
Cervix 16 1.57 0.90 2.56 43 3.07 2.22 4.14
Endometrium 43 0.76 0.55 1.03 118 1.41 1.16 1.69
Ovary 28 1.02 0.68 1.48 33 1.13 0.78 1.59
Female genital 14 1.41 0.77 2.37 16 1.90 1.08 3.1
Kidney 116 6.51 5.38 7.81 153 8.47 7.18 9.92
RCC 27 2.26 1.49 3.29 30 2.14 1.44 3.06
Renal pelvis 82 35.7 28.4 44.3 117 60.5 50.1 72.6
Ureter 83 87.8 70.0 108.9 49 69.9 51.5 92.1
Melanoma 33 0.97 0.67 1.37 44 1.00 0.73 1.35
Skin SCC 95 1.23 1.00 1.51 61 1.10 0.84 1.42
Nervous system 23 1.27 0.80 1.91 28 1.16 0.77 1.67
Thyroid 2 0.36 0.03 1.33 10 1.26 0.60 2.32
Endocrine 19 1.26 0.76 1.97 38 1.23 0.87 1.7
Connective tissue 4 0.89 0.23 2.31 6 1.37 0.49 2.99
NHL 31 1.02 0.69 1.45 26 0.94 0.61 1.37
Hodgkin lymphoma 1 0.72 0.00 4.12 2 1.21 0.11 4.45
Myeloma 8 0.61 0.26 1.21 9 0.95 0.43 1.81
Leukemia 34 1.26 0.87 1.76 27 1.23 0.81 1.79
All 1329 1.46 1.38 1.54 1359 1.47 1.39 1.55
Ureter CRC 7 2.22 0.88 4.60 9 2.13 0.97 4.06
Lung 6 4.10 1.48 8.99 2 1.98 0.19 7.29
Breast 12 2.33 1.20 4.09 17 1.50 0.87 2.4
Cervix 0 — — — 3 6.46 1.22 19.1
Endometrium 3 2.23 0.42 6.61 15 4.85 2.71 8.03
Female genital 1 4.04 0 23.17 2 6.95 0.66 25.6
Kidney 8 18.5 7.89 36.57 15 22.5 12.6 37.2
RCC 1 3.48 0.00 20.0 1 1.94 0 11.1
Renal pelvis 6 197.8 38.8 236.2 13 191.5 101.5 328.3
Bladder 49 69.9 51.5 92.1 83 87.8 70.0 108.9
All 94 3.88 3.13 4.75 159 4.74 4.03 5.54
Renal pelvis CRC 20 2.26 1.38 3.49 9 0.88 0.4 1.68
Lung 5 1.14 0.36 2.68 7 2.72 1.08 5.64
Breast 13 0.89 0.47 1.52 30 1.06 0.72 1.52
Cervix 0 — — — 2 1.66 0.16 6.10
Endometrium 4 1.02 0.27 2.64 14 1.88 1.02 3.16
Female genital 2 0.52 0 2.95 0 — — —
RCC 1 1.17 0 6.72 8 6.32 2.70 12.5
Bladder 117 60.5 50.1 72.6 82 35.7 28.4 44.3
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as SPC), nine individual FPCs were associated with an increased risk;
SIR of bladder cancer was highest after ureteral (69.9), renal pelvic
(60.5), and cervical (3.07) cancers. Notably, SIRs for bladder cancer
were increased after all female cancers (except ovarian cancer), includ-
ing genital (1.90) and endometrial (1.41) cancers. A bidirectional
increase in SIRs was found only for pelvic, ureteral, RCC, and lung can-
cers. The difference between bidirectional SIRs was significant for lung,
endometrial, and pelvic cancers; for the latter two cancers, bladder can-
cer risk was higher when diagnosed as SPC. The overall SIR was 1.47.
The data are summarized in Figure 1B.
After ureteral cancer, increased risks of SPCs were noted for renal
pelvic (197.8), bladder (69.9), lung (4.10), and breast (2.33) cancers
(Table 2). In the reverse order, SIRs of ureteral cancer were increased
after pelvic (191.5), bladder (87.8), cervical (6.46), and endometrial can-
cers (4.85). After pelvic cancer, second ureteral, bladder, and colorectal
(2.26) cancers were increased. In the reverse order, second pelvic can-
cer was increased after ureteral, bladder, lung (2.72), endometrial
(1.88), and RCC (6.32) cancers. Bladder cancer was by far themost com-
mon SPC after urethral and pelvic cancers.
We carried out analysis of risk of SPCs depending on the follow-up
time (1 year, 2-5 years, and >5 years) for male urothelial carcinomas
(Table S1). While the SIR was elevated for many SPCs in the first year of
follow-up, that of second lung, RCC, renal pelvic, and ureteral cancers
remained elevated throughout the follow-up time. Of note, second RCC
was significant only in the first follow-up period. Risk of second liver
cancer was increased in periods 1 and 2; UAT and stomach cancers and
leukemia only in period 2; and NHL only in period 3. Colorectal cancer
showed a borderline increase in periods 2 and 3. In the reverse order,
second bladder cancer risk was increased after ureteral, prostate, and
skin cancers through all periods; association with male genital cancers
was significant in periods 1; associations with UAT, colorectal, and lung
cancers were significant in periods 2 and 3; and associations with small
intestinal, testicular, connective tissue cancers, NHL, and Hodgkin
lymphoma were significant in the last period. For ureter and renal pelvic
cancers, only bladder and other UUT cancers were significant.
Similar analysis of risk of SPCs for female urothelial carcinomas is
shown in Table S2, and association between UUT sites was high through-
out the follow-up time. Risk of second lung cancers remained elevated
throughout the follow-up time. Risk of skin cancer was elevated in period
2 and nervous system cancer in period 3. Risk of breast cancer was ele-
vated after ureteral cancer in period 3. Risk of colorectal cancer was
increased after renal pelvic cancer in periods 1 and 2. In the reverse order,
bladder cancer as SPC, colorectal and cervical cancers were associated
with increased risk through all periods, and renal cell cancer in periods
1 and 2. Associations with breast and endometrial cancers were found in
periods 2 and 3, while thosewith ovarian and lung cancers included period
3. SIR of second ureter cancer was increased after endometrial cancer
(6.26) in the last period. Second renal pelvic cancer was increased after
colorectal cancer in periods 1 and 2.
Correlation coefficients for the pairwise SIRs were calculated for blad-
der cancer based on the main sites from Tables 1 and 2 (Table 4). Male vs
female Pearson correlation coefficient was 0.92 for SPC after bladder can-
cer and 0.88 in the reverse order (both P < .0001). For SPC vs FPC, the cor-
relation inmenwas 0.72 (P < .0002) and inwomen it was 0.92 (P < .0001).
4 | DISCUSSION
4.1 | Novel approach
The observation with direct clinical implications was the very high mutual
associations of bladder, ureteral, and renal pelvic cancers with each other
as FPC and SPCs. Although the recurrence risk is well known in urology, it
has never been defined before with the present precision.1,34,35 Among all
cancer considered, relative risks of 10 cancers were significant as SPCs
after bladder cancer, and second bladder cancer was significant after
TABLE 3 (Continued)
Cancer A Cancer B
Cancer A followed by cancer B Cancer B followed by cancer A
N SIR 95% CI N SIR 95% CI
Ureter 13 191.5 101.5 328.3 6 197.8 38.8 236.2
All 205 3.08 2.68 3.53 194 2.35 2.03 2.70
Note: Bold values show that the 95% CI does not overlap with 1.00.
Abbreviations: CRC, colorectal cancer; N, patient number; NHL, non-Hodgkin lymphoma; SCC squamous cell carcinoma; SIR, standardized incidence ratio;
SPC, second primary cancer; UAT, upper aerodigestive tract; 95% CI, 95% confidence interval.
TABLE 4 Correlation analysis between first and second primary cancers in men and women
Type of correlation No of pairs Pearson correlation coefficient P value
Men vs Women Risk of SPC after bladder cancer 18 0.92 <.0001
Risk of bladder cancer as SPC 18 0.88 <.0001
Risk of SPC vs risk as FPC Bladder in men 21 0.72 .0002
Bladder in women 20 0.92 <.0001
Note: Bold values show that the 95% CI does not overlap with 1.00.
Abbreviations: FPC, first primary cancer; SPC, second primary cancer.
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10 FPCs, only five male cancers showed a bidirectional association. For
women, four cancers were bidirectionally increased. Bidirectional associ-
ations of bladder cancer were shared for men and women for ureteral,
renal pelvic, RCC, and lung cancers. The correlation analysis showed high
concordance (P < .00021) between men and women when SPCs were
compared after bladder cancer or in the reverse order, bladder cancer as
SPC. Although previous studies have identified risks of smoking-related
SPCs after bladder cancer, the novel results in this study define bidirec-
tional risks betweenmany sites not related to smoking.19-22
In the below discussion, we compare the consistency of the
results internally and externally (with published literature) and specu-
late about the putative mechanisms, keeping in mind the limitations of
observational epidemiology.
4.2 | Urological sites
Urothelial carcinomas have been described as a pan-urothelial disease
with a propensity to recur throughout these sites.24,36 As withmany other
cancers, even intratumoral heterogenicity has been described.37 However,
a recent literature review concluded that most recurrent urothelial tumors
are monoclonal which would imply that the mechanism of spread would
be intraluminal seeding or intraepithelial migration.24 These in turn would
imply that the direction of urine flow and anatomic vicinity would play a
role. In a Spanish study, concomitant primary urothelial tumorswere found
in 17% of the patients.36 The likelihood of finding a concomitant bladder
cancer increased by anatomic location of the primary tumor, being 10, 18,
and 33% in patients with primary caliceal/renal pelvic, upper ureteral, and
lower ureteral cancers, in line with the above predictions. The pan-
urothelial disease is the likely explanation why the risks among urothelial
sites far exceeded those between urothelial and nonurothelial sites.
In the present study, the male risk of second bladder cancer was
equally high (SIR 21) when renal pelvic or ureteral cancers were FPCs,
but, for women, the risks were slightly higher after ureteral (69.9) than
after pelvic (60.5) cancers. Most urothelial cancer associations were
higher in women than in men. The female SIRs were more than doubled
and significantly higher compared to male rates for FCP-SPC pairs of
bladder-pelvis (SIR in women 35.7), pelvis-bladder (60.5), bladder-
ureter (87.8), and ureter-bladder (69.9). Although the risks were highest
during the year of diagnosis, they persisted often to follow-up period of
>5 years (conditional on patient survival). These risks were exquisitely
high and clinically relevant, motivating an extended patient follow-up.
Bladder cancer was by far the most common SPC after first ureteral
and renal pelvic cancers, accounting for at least half of all SPCs.
Of urological interest is also the possible SPC risks between bladder,
RCC, and prostate cancers. The SIRs for second male RCC and prostate
cancer were 2.20 and 1.73, respectively, and prostate cancer accounted
for 44% of all SPCs after bladder cancer. Male SIRs for bladder cancer as
SPC after these cancers were more modest, 1.45 and 1.25, respectively,
but second bladder cancer following prostate cancer accounted for 51%
of all bladder cancers as SPC. SIR for second RCC in women was 2.26
and in the reverse order 2.14. However, when analyzed by follow-up
time, the risk for second prostate cancer was increased only in the year
of bladder cancer diagnosis, which suggests that the excess risk was due
to surveillance bias. The conclusion about second RCC was similar for
men but for women remained unclear. Thus, the study provided no evi-
dence for association of urothelial cancers and RCCor prostate cancer.
4.3 | Urological with other sites
For the other cancers, we considered the multiple independent results for
consistency in order to conclude about true associations. These included
results between both sexes in bidirectional analysis and, in order to exclude
surveillance bias, only considering the follow-up times 2-5 years and
>5 years after diagnosis of FPC (thus yielding eight comparisons for can-
cers diagnosed in both sexes). Lung cancer was significant in seven associa-
tions, colorectal cancer in four, UAT, prostate, and skin cancers in three,
and breast, cervical, and endometrial cancers and non-Hodgkin lymphoma
in two. The associations with lung and upper aerodigestive tract cancers
were most likely related to smoking and that of prostate cancer to residual
surveillance bias. The risk for cervical cancer (and, for female, genital cancer)
was most likely an example of long-term surveillance bias, considering risk
reduction along the follow-up time, anatomic vicinity, and knownviral etiol-
ogy.Wehave previously observed such long-term surveillance bias for uro-
lithiasis with various cancers, particularly for cancers in anatomic vicinity.38
In another study on female vaginal and vulvar cancer, which share the viral
etiology with cervical cancer, we have shown that the risk for second blad-
der cancerwas 1.88 (N= 45, 95%CI 1.35-2.44).39
The associations of bladder, ureteral, and renal pelvic cancers
with colorectal, small intestinal, endometrial, and ovarian cancers may
signal the contribution of genetic factors. Bladder cancer is considered
a minor component in Lynch syndrome (hereditary nonpolyposis colo-
rectal cancer syndrome), caused by germline mutations in mismatch
repair genes.7 It is plausible that the increased risks of second ureteral
(4.85) and pelvic (1.88) cancers after endometrial cancer were contrib-
uted by Lynch syndrome.10,11 The reason for the higher associations
of the Lynch syndrome-related cancers in women compared to men
may be due to the lower female population incidence of urothelial
cancers, particularly of bladder cancer. The difference in population
incidence was probably in part related to historic higher smoking level
in men compared to women, as pointed out in Introduction. However,
as in all population level studies, we lacked the definitive genetic evi-
dence, but want to remind that the diagnostic guidelines based on the
Amsterdam or Bethesda criteria emphasize family history.40
Among the remaining associations with bladder cancer, using the
above criteria for consistency, skin SCC had three and non-Hodgkin lym-
phoma two associations. The commondenominator for these two cancer
is that they are a hallmark of immune disturbance and are vastly elevated
in immune suppressed patients.41,42 It is thus plausible that immune dys-
functionsmay contribute to the associations of bladder cancers with skin
cancer andNHL.41 Finally, there were solitary associations for male blad-
der cancers as SPC, which emerged >5 years after diagnosis of testicular
cancer and Hodgkin lymphoma. These are early-onset cancers treated
with intense chemotherapy and/or radiotherapy with high risk of SPCs,
including bladder cancer.43-45
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4.4 | Strengths and limitations
This study has a number of strengths, the foremost being a nation-
wide coverage and access to a high-level cancer registry data.31,46
Because of linkage to the censuses, we had information on socio-
economic and residential background data covering the whole popu-
lation, which is unique in nation-wide studies. Socio-economic data
are highly correlated with lung cancer incidence in Sweden and thus
provide a proxy of smoking level.47-49 This kind of studies with
numerous comparisons will produce some significant associations by
chance. Assessing both sexes separately and comparing the consis-
tency was helpful in avoiding chance findings. The bidirectional
design is another strength in helping to interpret the associations.
Ureteral and renal pelvic cancers are rare, and all related case num-
bers were low, affording low statistical power. The major limitation
was that data on treatment were lacking, but we assume that surgery
has been the primary treatment for bladder and UUT cancers.
5 | CONCLUSIONS
We showed that many cancers were associated with bladder cancer
as SPCs or, in the reverse order, bladder cancer as SPC. The risks of
recurrence of urothelial cancers were very high, and, at most sites,
female risks were twice over the male risks. Risks persisted often
through follow-up periods of >5 years, motivating an extended
patient follow-up. Apart from smoking-related cancers, immune dys-
function was suggested to contribute to associations with skin cancer
and non-Hodgkin lymphoma. Lynch syndrome-related cancers were
associated with urothelial cancers, providing population-level justification
for diagnostic and management recommendations.1
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